Clinical Trial Update: LUtetium-177 DOsimetry as a Predictive Biomarker of Response in Metastatic Prostate Cancer Patients Treated With PSMA Radioligand THerapy.

View source ↗

Summary

This clinical trial investigates using Lutetium-177 dosimetry as a predictive biomarker of response for metastatic prostate cancer patients treated with PSMA ra…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Lutetium-177 PSMA-617 (lutetium Lu-177 PSMA-617)

Snippet

Sponsor: Jules Bordet Institute | Conditions: Prostate Cancer (Adenocarcinoma) | Status: RECRUITING